Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Improvement In Self-Reported Physical Functioning With Tiotropium/Olodaterol In Central And Eastern European COPD Patients

A. Valipour, M. Tamm, J. Kociánová, V. Bayer, M. Sanzharovskaya, A. Medvedchikov, M. Haaksma-Herczegh, J. Mucsi, Z. Fridlender, C. Toma, A. Belevskiy, B. Matula, J. Šorli,

. 2019 ; 14 (-) : 2343-2354. [pub] 20191011

Jazyk angličtina Země Nový Zéland

Typ dokumentu časopisecké články, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023593

Background: Reduced physical activity is associated with increased morbidity and mortality in patients with COPD. Studies suggest that treatment with the long-acting muscarinic antagonist tiotropium and the long-acting β2-agonist olodaterol increases exercise capacity. This study assessed the effects of a fixed-dose combination (FDC) of tiotropium/olodaterol (delivered via Respimat®) on physical functioning in patients with stable COPD in a "real-world setting". Methods: An international, open-label, single-arm, non-interventional study conducted in nine countries measuring changes in self-reported physical functioning in COPD patients treated with tiotropium/olodaterol 5/5 μg FDC for approximately 6 weeks. The primary endpoint was therapeutic success, defined as a minimum 10-point increase in the 10-question Physical Functioning Questionnaire (PF-10) score. Secondary endpoints included absolute change in PF-10 from Visit 1 to Visit 2, patient general condition (measured by Physician's Global Evaluation score) and patient satisfaction with the treatment and device (assessed by Patient Satisfaction Questionnaire at the end of the study period). Results: Therapeutic success was observed in 67.8% of 7218 patients (95% CI 66.7, 68.8) in the final analysis set after approximately 6 weeks of treatment with tiotropium/olodaterol. Mean change in PF-10 score between Visit 1 and Visit 2 was 16.6 points (95% CI 16.2, 17.0). Therapeutic success was 64.3% (95% CI 63.0-65.6%) in patients with infrequent (≤1) and 76.1% (95% CI 74.3-77.9%) in patients with frequent (≥2) exacerbations (p<0.0001). Patient general condition improved as indicated by an improvement in Physician's Global Evaluation scores between visits. Most patients were very satisfied or satisfied with tiotropium/olodaterol treatment in general (81%), reported inhalation satisfaction (85%), and satisfactory handling of the device (84%). 1.3% of patients reported an investigator-defined drug-related adverse event. Conclusion: Treatment with tiotropium/olodaterol led to an improvement in self-reported physical functioning in patients with COPD.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023593
003      
CZ-PrNML
005      
20201214130518.0
007      
ta
008      
201125s2019 nz f 000 0|eng||
009      
AR
024    7_
$a 10.2147/COPD.S204388 $2 doi
035    __
$a (PubMed)31632003
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Valipour, Arschang $u Department of Respiratory and Critical Care Medicine, Karl-Landsteiner-Institute for Lung Research and Pulmonary Oncology, Krankenhaus Nord - Klinik Floridsdorf, Vienna, Austria.
245    10
$a Improvement In Self-Reported Physical Functioning With Tiotropium/Olodaterol In Central And Eastern European COPD Patients / $c A. Valipour, M. Tamm, J. Kociánová, V. Bayer, M. Sanzharovskaya, A. Medvedchikov, M. Haaksma-Herczegh, J. Mucsi, Z. Fridlender, C. Toma, A. Belevskiy, B. Matula, J. Šorli,
520    9_
$a Background: Reduced physical activity is associated with increased morbidity and mortality in patients with COPD. Studies suggest that treatment with the long-acting muscarinic antagonist tiotropium and the long-acting β2-agonist olodaterol increases exercise capacity. This study assessed the effects of a fixed-dose combination (FDC) of tiotropium/olodaterol (delivered via Respimat®) on physical functioning in patients with stable COPD in a "real-world setting". Methods: An international, open-label, single-arm, non-interventional study conducted in nine countries measuring changes in self-reported physical functioning in COPD patients treated with tiotropium/olodaterol 5/5 μg FDC for approximately 6 weeks. The primary endpoint was therapeutic success, defined as a minimum 10-point increase in the 10-question Physical Functioning Questionnaire (PF-10) score. Secondary endpoints included absolute change in PF-10 from Visit 1 to Visit 2, patient general condition (measured by Physician's Global Evaluation score) and patient satisfaction with the treatment and device (assessed by Patient Satisfaction Questionnaire at the end of the study period). Results: Therapeutic success was observed in 67.8% of 7218 patients (95% CI 66.7, 68.8) in the final analysis set after approximately 6 weeks of treatment with tiotropium/olodaterol. Mean change in PF-10 score between Visit 1 and Visit 2 was 16.6 points (95% CI 16.2, 17.0). Therapeutic success was 64.3% (95% CI 63.0-65.6%) in patients with infrequent (≤1) and 76.1% (95% CI 74.3-77.9%) in patients with frequent (≥2) exacerbations (p<0.0001). Patient general condition improved as indicated by an improvement in Physician's Global Evaluation scores between visits. Most patients were very satisfied or satisfied with tiotropium/olodaterol treatment in general (81%), reported inhalation satisfaction (85%), and satisfactory handling of the device (84%). 1.3% of patients reported an investigator-defined drug-related adverse event. Conclusion: Treatment with tiotropium/olodaterol led to an improvement in self-reported physical functioning in patients with COPD.
650    _2
$a senioři $7 D000368
650    _2
$a benzoxaziny $x terapeutické užití $7 D048588
650    _2
$a fixní kombinace léků $7 D004338
650    _2
$a cvičení $x fyziologie $7 D015444
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a chronická obstrukční plicní nemoc $x farmakoterapie $x patofyziologie $7 D029424
650    12
$a zpráva o sobě $7 D057566
650    _2
$a tiotropium bromid $x terapeutické užití $7 D000069447
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Tamm, Michael $u Lung Centre/Pneumology Department, University Hospital Basel, Basel, Switzerland.
700    1_
$a Kociánová, Jana $u Pneumological Outpatient Department, MephaCentrum, a.s., Ostrava-Poruba, Czech Republic.
700    1_
$a Bayer, Valentina $u Biostatistics and Data Sciences, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
700    1_
$a Sanzharovskaya, Maria $u Respiratory TA, Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, Austria.
700    1_
$a Medvedchikov, Alexey $u Medical Affairs Regional Center, Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, Austria.
700    1_
$a Haaksma-Herczegh, Monika $u Medical Affairs Regional Center, Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, Austria.
700    1_
$a Mucsi, János $u Elizabeth Nursing Home, Gödöllő, Hungary.
700    1_
$a Fridlender, Zvi $u Department of Internal Medicine, Hebrew University Hadassah Medical School, Jerusalem, Israel.
700    1_
$a Toma, Claudia $u Department of Pneumology, Institute of Pneumatology "Marius Nasta", Bucharest, Romania. Department Of Pneumology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
700    1_
$a Belevskiy, Andrey $u Department of Pulmonology, Pirogov Russian National Research Medical University, Pletnev Hospital, Moscow, Russian Federation.
700    1_
$a Matula, Bohumil $u Department of Functional Diagnostics, Specialized Hospital of Saint Zoerardus, Teaching Facility of the Slovak Medical University, Nitra, Slovakia.
700    1_
$a Šorli, Jurij $u Topolšica Hospital, Topolšica, Slovenia.
773    0_
$w MED00165283 $t International journal of chronic obstructive pulmonary disease $x 1178-2005 $g Roč. 14, č. - (2019), s. 2343-2354
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31632003 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214130516 $b ABA008
999    __
$a ok $b bmc $g 1595912 $s 1114269
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 14 $c - $d 2343-2354 $e 20191011 $i 1178-2005 $m International journal of COPD $n Int. j. chronic obstr. pulm. dis. $x MED00165283
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace